Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Phenylketonuria (PKU) Market from 2024 to 2025?
The market size for phenylketonuria (PKU) has seen a robust expansion in preceding years. An ascent from $0.85 billion in 2024 to $0.93 billion in 2025 is expected, marking a compound annual growth rate (CAGR) of 9.1%. Factors contributing to the growth during the historic period include the amplification of newborn screening initiatives, heightened understanding of metabolic disorders, enhanced management of PKU dietary needs, increased access to medical foods, and the sanction of regulatory approvals for PKU treatments.
What Is the Projected Market Size of the Phenylketonuria (PKU) Market?
The market for phenylketonuria (PKU) is projected to witness robust expansion in the upcoming years, reaching a valuation of $1.30 billion by 2029 at an 8.8% compound annual growth rate (CAGR). This surge within the predicted timeframe can be ascribed to factors such as the growing acceptance of gene therapy, proliferation of enzyme replacement therapies, increased funding for rare disease studies, escalating demand for personalized medication, and governmental backing for PKU treatment coverage. Key trends anticipated in this forecast period encompass the emergence of RNA-based therapies, the advancement of digital health measures for handling PKU, increasing partnerships amongst biotech corporations and research bodies, emphasis on non-dietary treatment options, and the augmentation of telehealth services for PKU patients.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21257&type=smp
Who are the Major Competitors in the Phenylketonuria (PKU) Market Outlook?
Major companies operating in the phenylketonuria (PKU) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company, LLC, Relief Therapeutics Holding SA, SOM Innovation Biotech S.A., Synlogic Inc., Galen Ltd, Aptatek Biosciences Inc., Homology Medicines Inc
What Is Fueling Growth in the Phenylketonuria (PKU) Market?
The escalation in the instances of genetic disorders is foreseen to bolster the development of the phenylketonuria (PKU) market in the future. Genetic disorders are health conditions triggered by anomalies in a person’s DNA, such as gene mutations, deletions, or duplications. The surge in incidents of genetic disorders can be linked to variables like advancing maternal age, environmental influences, technological progress in diagnostics, and increased awareness leading to better detection rates. Phenylketonuria aids the comprehension of genetic disorders by depicting how inherited enzyme deficiencies can result in serious metabolic issues. For example, as reported by Gene People, a UK-based registered charity in March 2024, genetic conditions impact an estimated 1 in 25 children, affecting over 2.4 million children and adults in the UK. Moreover, almost 30,000 infants and children in the UK are diagnosed with a genetic condition each year. Consequently, the surge in instances of genetic disorders is steering the growth of the phenylketonuria (PKU) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21257&type=smp
Which Phenylketonuria (PKU) Market Segments Are Growing the Fastest?
The phenylketonuria (PKU) market covered in this report is segmented –
1) By Type: Hyperphenylalaninemia, Mild Phenylketonuria (PKU), Moderate And Variant, Classic Phenylketonuria (PKU)
2) By Treatment Type: Enzyme Replacement Therapy, Gene Therapy, Medication, Dietary Therapy
3) By Diagnosis: Genetic Testing, Biochemical Testing, Newborn Screening
4) By End-User: Specialty Clinics, Research Institutes, Home Healthcare, Hospitals
Subsegments:
1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia, Moderate Hyperphenylalaninemia, Severe Hyperphenylalaninemia
2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management, Mild PKU with enzyme supplementation
3) By Moderate And Variant: Moderate PKU with medication, Variant PKU with treatment variations
4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management, Classic PKU with enzyme replacement therapy
Which Industry Trends Are Shaping the Future of the Phenylketonuria (PKU) Market?
Leading firms in the phenylketonuria (PKU) market are emphasizing the augmentation of groundbreaking products through the utilization of numerous technologies, like the physiognomic technology. The aim is to fortify the effectiveness and safety of PKU therapies by mirroring human physiological conditions to optimize drug absorption and metabolism. Physiomimic technology entails an extensive combination of hardware, consumables, and assay protocols created to mirror intricate human biology and predict human drug responses with accuracy. For example, in October 2022, Relief Therapeutics Holding SA, a bio-pharmaceutical firm based in Switzerland, introduced PKU Golike. PKU Golike represents a next-generation medicinal food product, developed using patented, pharmaceutical-grade Physiomimic technology for managing the dietary needs of phenylketonuria (PKU) patients. PKU Golike, available as granules, packets, and medicinal food bars, offers a unique coating for the physiological absorption of amino acids, akin to natural proteins, while hiding their unfavourable taste, smell, and aftertaste.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/phenylketonuria-pku-global-market-report
Which Countries Are Leading the Phenylketonuria (PKU) Market?
North America was the largest region in the phenylketonuria (PKU) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the phenylketonuria (PKU) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21257
This Report Delivers Insight On:
1. How big is the phenylketonuria (pku) market, and how is it changing globally?
2. Who are the major companies in the phenylketonuria (pku) market, and how are they performing?
3. What are the key opportunities and risks in the phenylketonuria (pku) market right now?
4. Which products or customer segments are growing the most in the phenylketonuria (pku) market?
5. What factors are helping or slowing down the growth of the phenylketonuria (pku) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model